Ignite Creation Date:
2024-05-05 @ 9:53 AM
Last Modification Date:
2024-10-26 @ 9:01 AM
Study NCT ID:
NCT00000298
Status:
COMPLETED
Last Update Posted:
2005-08-17
First Post:
1999-09-20
Brief Title:
Buprenorphine Combination Tablet Feasibility - 1
Sponsor:
National Institute on Drug Abuse NIDA
Organization:
National Institute on Drug Abuse NIDA
Study Overview
Official Title:
Buprenorphine Combination Tablet Feasibility
Status:
COMPLETED
Status Verified Date:
1996-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to determine target dose range of buprenorphinenaloxone combination tablet that provides therapeutic response in opiate addicts with low to moderate dependence and to identify appropriate initial induction dose in opiate addicts with low to moderate dependence
Detailed Description:
None
Study Oversight
Has Oversight DMC:
Is a FDA Regulated Drug?:
Is a FDA Regulated Device?:
Is an Unapproved Device?:
Is a PPSD?:
Is a US Export?:
Is an FDA AA801 Violation?:
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| P50-09260-1 | None | None | None |